cardiovascular research graphical abstract

CVIA Journal

Graphical abstracts now mandatory for all original and review article submissions.

A well-designed, visually engaging Graphical Abstract enhances an article’s impact by facilitating faster comprehension, encouraging interdisciplinary interest, and increasing visibility—especially on social media platforms. The Graphical Abstract should succinctly summarize the article in a visually engaging format, aimed at capturing the interest of a broad audience.

Privacy Overview

Research articles should report on original primary research.

Graphical abstract image

Submission of a Graphical Abstract image is strongly recommended and, together with the article title and the abstract text, should provide the reader with a visual description of the topic covered in the Research article. This is a picture which will appear underneath the Abstract on the Cardiovascular Diabetology website. It should be relevant to the topic covered and serve to attract readers' attention to the article. The graphical abstract image may be one of the images included in the article or any other image the authors feel to be appropriate. It may be a composite of more than one image. It should be approximately 920x300 pixels and should be uploaded as a JPEG, PNG or SVG file. The graphical abstract may have a caption of up to 30 words. This caption must be a part of the image file and must be below the picture. Please note that graphical abstract images must comply with Springer's copyright policy.

Research Insights

Cardiovascular Diabetology encourages authors of research articles, systematic reviews and meta analyses to add a “Research Insights” summary (< 200 words ) below the abstract to include the following questions along with the responses:

• What is currently known about this topic? (max. 3 highlights)
• What is the key research question? (formatted as a question)
• What is new? (max. 3 highlights)
• How might this study influence clinical practice? (max. 1 highlight)

Please note that each highlight should be no more than 100 characters including spaces and punctuation.  Please upload this as a table .

An example for a Research Insights:

Preparing your manuscript

The information below details the section headings that you should include in your manuscript and what information should be within each section.

Please note that your manuscript must include a 'Declarations' section including all of the subheadings (please see below for more information).

The title page should:

• "A versus B in the treatment of C: a randomized controlled trial", "X is a risk factor for Y: a case control study", "What is the impact of factor X on subject Y: A systematic review"
• or for non-clinical or non-research studies a description of what the article reports
• if a collaboration group should be listed as an author, please list the Group name as an author. If you would like the names of the individual members of the Group to be searchable through their individual PubMed records, please include this information in the “Acknowledgements” section in accordance with the instructions below
• Large Language Models (LLMs), such as ChatGPT , do not currently satisfy our authorship criteria . Notably an attribution of authorship carries with it accountability for the work, which cannot be effectively applied to LLMs. Use of an LLM should be properly documented in the Methods section (and if a Methods section is not available, in a suitable alternative part) of the manuscript.
• indicate the corresponding author

The Abstract should not exceed 350 words. Please minimize the use of abbreviations and do not cite references in the abstract. Reports of randomized controlled trials should follow the CONSORT extension for abstracts. The abstract must include the following separate sections:

• Background: the context and purpose of the study
• Methods: how the study was performed and statistical tests used
• Results: the main findings
• Conclusions: brief summary and potential implications
• Trial registration: If your article reports the results of a health care intervention on human participants, it must be registered in an appropriate registry and the registration number and date of registration should be stated in this section. If it was not registered prospectively (before enrollment of the first participant), you should include the words 'retrospectively registered'. See our editorial policies for more information on trial registration

Three to ten keywords representing the main content of the article.

The Background section should explain the background to the study, its aims, a summary of the existing literature and why this study was necessary or its contribution to the field.

The methods section should include:

• the aim, design and setting of the study
• the characteristics of participants or description of materials
• a clear description of all processes, interventions and comparisons. Generic drug names should generally be used. When proprietary brands are used in research, include the brand names in parentheses
• the type of statistical analysis used, including a power calculation if appropriate

This should include the findings of the study including, if appropriate, results of statistical analysis which must be included either in the text or as tables and figures.

This section should discuss the implications of the findings in context of existing research and highlight limitations of the study.

Conclusions

This should state clearly the main conclusions and provide an explanation of the importance and relevance of the study reported.

List of abbreviations

If abbreviations are used in the text they should be defined in the text at first use, and a list of abbreviations should be provided.

Declarations

All manuscripts must contain the following sections under the heading 'Declarations':

Ethics approval and consent to participate

Consent for publication, availability of data and materials, competing interests, authors' contributions, acknowledgements.

• Authors' information (optional)

Please see below for details on the information to be included in these sections.

If any of the sections are not relevant to your manuscript, please include the heading and write 'Not applicable' for that section. 

Manuscripts reporting studies involving human participants, human data or human tissue must:

• include a statement on ethics approval and consent (even where the need for approval was waived)
• include the name of the ethics committee that approved the study and the committee’s reference number if appropriate

Studies involving animals must include a statement on ethics approval and for experimental studies involving client-owned animals, authors must also include a statement on informed consent from the client or owner.

See our editorial policies for more information.

If your manuscript does not report on or involve the use of any animal or human data or tissue, please state “Not applicable” in this section.

If your manuscript contains any individual person’s data in any form (including any individual details, images or videos), consent for publication must be obtained from that person, or in the case of children, their parent or legal guardian. All presentations of case reports must have consent for publication.

You can use your institutional consent form or our consent form if you prefer. You should not send the form to us on submission, but we may request to see a copy at any stage (including after publication).

See our editorial policies for more information on consent for publication.

If your manuscript does not contain data from any individual person, please state “Not applicable” in this section.

All manuscripts must include an ‘Availability of data and materials’ statement. Data availability statements should include information on where data supporting the results reported in the article can be found including, where applicable, hyperlinks to publicly archived datasets analysed or generated during the study. By data we mean the minimal dataset that would be necessary to interpret, replicate and build upon the findings reported in the article. We recognise it is not always possible to share research data publicly, for instance when individual privacy could be compromised, and in such instances data availability should still be stated in the manuscript along with any conditions for access.

Authors are also encouraged to preserve search strings on searchRxiv https://searchrxiv.org/ , an archive to support researchers to report, store and share their searches consistently and to enable them to review and re-use existing searches. searchRxiv enables researchers to obtain a digital object identifier (DOI) for their search, allowing it to be cited. 

Data availability statements can take one of the following forms (or a combination of more than one if required for multiple datasets):

• The datasets generated and/or analysed during the current study are available in the [NAME] repository, [PERSISTENT WEB LINK TO DATASETS]
• The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
• All data generated or analysed during this study are included in this published article [and its supplementary information files].
• The datasets generated and/or analysed during the current study are not publicly available due [REASON WHY DATA ARE NOT PUBLIC] but are available from the corresponding author on reasonable request.
• Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.
• The data that support the findings of this study are available from [third party name] but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of [third party name].
• Not applicable. If your manuscript does not contain any data, please state 'Not applicable' in this section.

More examples of template data availability statements, which include examples of openly available and restricted access datasets, are available here .

BioMed Central strongly encourages the citation of any publicly available data on which the conclusions of the paper rely in the manuscript. Data citations should include a persistent identifier (such as a DOI) and should ideally be included in the reference list. Citations of datasets, when they appear in the reference list, should include the minimum information recommended by DataCite and follow journal style. Dataset identifiers including DOIs should be expressed as full URLs. For example:

Hao Z, AghaKouchak A, Nakhjiri N, Farahmand A. Global integrated drought monitoring and prediction system (GIDMaPS) data sets. figshare. 2014. http://dx.doi.org/10.6084/m9.figshare.853801

With the corresponding text in the Availability of data and materials statement:

The datasets generated during and/or analysed during the current study are available in the [NAME] repository, [PERSISTENT WEB LINK TO DATASETS]. [Reference number]  

If you wish to co-submit a data note describing your data to be published in BMC Research Notes , you can do so by visiting our submission portal . Data notes support open data and help authors to comply with funder policies on data sharing. Co-published data notes will be linked to the research article the data support ( example ).

All financial and non-financial competing interests must be declared in this section.

See our editorial policies for a full explanation of competing interests. If you are unsure whether you or any of your co-authors have a competing interest please contact the editorial office.

Please use the authors initials to refer to each authors' competing interests in this section.

If you do not have any competing interests, please state "The authors declare that they have no competing interests" in this section.

All sources of funding for the research reported should be declared. If the funder has a specific role in the conceptualization, design, data collection, analysis, decision to publish, or preparation of the manuscript, this should be declared.

The individual contributions of authors to the manuscript should be specified in this section. Guidance and criteria for authorship can be found in our editorial policies .

Please use initials to refer to each author's contribution in this section, for example: "FC analyzed and interpreted the patient data regarding the hematological disease and the transplant. RH performed the histological examination of the kidney, and was a major contributor in writing the manuscript. All authors read and approved the final manuscript."

Please acknowledge anyone who contributed towards the article who does not meet the criteria for authorship including anyone who provided professional writing services or materials.

Authors should obtain permission to acknowledge from all those mentioned in the Acknowledgements section.

See our editorial policies for a full explanation of acknowledgements and authorship criteria.

If you do not have anyone to acknowledge, please write "Not applicable" in this section.

Group authorship (for manuscripts involving a collaboration group): if you would like the names of the individual members of a collaboration Group to be searchable through their individual PubMed records, please ensure that the title of the collaboration Group is included on the title page and in the submission system and also include collaborating author names as the last paragraph of the “Acknowledgements” section. Please add authors in the format First Name, Middle initial(s) (optional), Last Name. You can add institution or country information for each author if you wish, but this should be consistent across all authors.

Please note that individual names may not be present in the PubMed record at the time a published article is initially included in PubMed as it takes PubMed additional time to code this information.

Authors' information

This section is optional.

You may choose to use this section to include any relevant information about the author(s) that may aid the reader's interpretation of the article, and understand the standpoint of the author(s). This may include details about the authors' qualifications, current positions they hold at institutions or societies, or any other relevant background information. Please refer to authors using their initials. Note this section should not be used to describe any competing interests.

Footnotes can be used to give additional information, which may include the citation of a reference included in the reference list. They should not consist solely of a reference citation, and they should never include the bibliographic details of a reference. They should also not contain any figures or tables.

Footnotes to the text are numbered consecutively; those to tables should be indicated by superscript lower-case letters (or asterisks for significance values and other statistical data). Footnotes to the title or the authors of the article are not given reference symbols.

Always use footnotes instead of endnotes.

Examples of the Vancouver reference style are shown below.

See our editorial policies for author guidance on good citation practice

Web links and URLs: All web links and URLs, including links to the authors' own websites, should be given a reference number and included in the reference list rather than within the text of the manuscript. They should be provided in full, including both the title of the site and the URL, as well as the date the site was accessed, in the following format: The Mouse Tumor Biology Database. http://tumor.informatics.jax.org/mtbwi/index.do . Accessed 20 May 2013. If an author or group of authors can clearly be associated with a web link, such as for weblogs, then they should be included in the reference.

Example reference style:

Article within a journal

Smith JJ. The world of science. Am J Sci. 1999;36:234-5.

Article within a journal (no page numbers)

Rohrmann S, Overvad K, Bueno-de-Mesquita HB, Jakobsen MU, Egeberg R, Tjønneland A, et al. Meat consumption and mortality - results from the European Prospective Investigation into Cancer and Nutrition. BMC Medicine. 2013;11:63.

Article within a journal by DOI

Slifka MK, Whitton JL. Clinical implications of dysregulated cytokine production. Dig J Mol Med. 2000; doi:10.1007/s801090000086.

Article within a journal supplement

Frumin AM, Nussbaum J, Esposito M. Functional asplenia: demonstration of splenic activity by bone marrow scan. Blood 1979;59 Suppl 1:26-32.

Book chapter, or an article within a book

Wyllie AH, Kerr JFR, Currie AR. Cell death: the significance of apoptosis. In: Bourne GH, Danielli JF, Jeon KW, editors. International review of cytology. London: Academic; 1980. p. 251-306.

OnlineFirst chapter in a series (without a volume designation but with a DOI)

Saito Y, Hyuga H. Rate equation approaches to amplification of enantiomeric excess and chiral symmetry breaking. Top Curr Chem. 2007. doi:10.1007/128_2006_108.

Complete book, authored

Blenkinsopp A, Paxton P. Symptoms in the pharmacy: a guide to the management of common illness. 3rd ed. Oxford: Blackwell Science; 1998.

Online document

Doe J. Title of subordinate document. In: The dictionary of substances and their effects. Royal Society of Chemistry. 1999. http://www.rsc.org/dose/title of subordinate document. Accessed 15 Jan 1999.

Online database

Healthwise Knowledgebase. US Pharmacopeia, Rockville. 1998. http://www.healthwise.org. Accessed 21 Sept 1998.

Supplementary material/private homepage

Doe J. Title of supplementary material. 2000. http://www.privatehomepage.com. Accessed 22 Feb 2000.

University site

Doe, J: Title of preprint. http://www.uni-heidelberg.de/mydata.html (1999). Accessed 25 Dec 1999.

Doe, J: Trivial HTTP, RFC2169. ftp://ftp.isi.edu/in-notes/rfc2169.txt (1999). Accessed 12 Nov 1999.

Organization site

ISSN International Centre: The ISSN register. http://www.issn.org (2006). Accessed 20 Feb 2007.

Dataset with persistent identifier

Zheng L-Y, Guo X-S, He B, Sun L-J, Peng Y, Dong S-S, et al. Genome data from sweet and grain sorghum (Sorghum bicolor). GigaScience Database. 2011. http://dx.doi.org/10.5524/100012 .

Figures, tables and additional files

See  General formatting guidelines  for information on how to format figures, tables and additional files.

Submit manuscript

• Editorial Board
• Manuscript editing services
• Instructions for Editors
• Contact Support for Editors
• Sign up for article alerts and news from this journal

Annual Journal Metrics

Citation Impact 2023 Journal Impact Factor: 8.5 5-year Journal Impact Factor: 8.9 Source Normalized Impact per Paper (SNIP): 1.855 SCImago Journal Rank (SJR): 2.621

Speed 2023 Submission to first editorial decision (median days): 2 Submission to acceptance (median days): 56

Usage 2023 Downloads: 2,523,778 Altmetric mentions: 3,115

• More about our metrics

Cardiovascular Diabetology

ISSN: 1475-2840

• Submission enquiries: [email protected]

• Search Menu
• Sign in through your institution
• Advance Articles
• Editor's Choice
• Supplements

Spotlight Issues

• Image Gallery
• ESC Journals App
• ESC Content Collections
• Author Guidelines
• Submission Site
• Why publish with CVR?
• Open Access Options
• Read & Publish
• Author Resources
• Self-Archiving Policy
• About Cardiovascular Research
• About the European Society of Cardiology
• ESC Publications
• Journal Career Network
• Editorial Board
• ESC membership
• Advertising and Corporate Services
• Developing Countries Initiative
• Dispatch Dates
• Terms and Conditions
• Journals on Oxford Academic
• Books on Oxford Academic

Latest articles

Editor's Choice

Discover the top 5 reasons to publish your research with  Cardiovascular Research :

• A global leader in discovery and translational cardiovascular science
• Worldwide visibility through a wide range of channels
• Top quality peer review by international experts
• Simple submission and fast decisions
• Option to publish open access

Learn more and join our prestigious author community

NEW: Spotlight Issue

Discover Cardiovascular Research 's latest Spotlight Issue on Obesity, Metabolism, and Diabetes. This issue contains a number of invited expert reviews alongside original research papers.

Start reading

IMPACT FACTOR

CARDIAC & CARDIOVASCULAR SYSTEMS

12 out of 220

JOURNAL CITATION INDICATOR

Obesity, Metabolism, and Diabetes

Read the Spotlight Issue

Heart Failure

Cardiovascular Immunology

Browse all the Cardiovascular Research Spotlight Issues

CVR Discoveries

Enjoy the new webinar series delivered by  Cardiovascular Research  and the ESC Council on Basic Cardiovascular Science.

Watch the webinars

CVR On life

Cardiovascular Research On life is the online platform linking the journal with the wider scientific community.

Find out more

Follow @CVR_TomaszGuzik on X

Connect with Editor-in-Chief, Tomasz J. Guzik, and stay up to date with the latest news and content from CVR .

Join the conversation with #CardiovascularResearch

War in Ukraine

ESC Journal Family editors-in-chief fully support the  official ESC statement .

From the ESC

Discover the  Cardiovascular Research articles that are making an impact! Read the top 15 most cited articles published in the last 12 months.

Explore the Collection

Discover Cardiovascular Research ’s top 20 most read articles published within the past 12 months.

Explore the collection

Discover the ESC Content Collections hub, now home to the latest content and collections from the ESC publications.

Read the latest collections

Visit the ESC Publications website to browse journals, books, guidelines, and online resources from the ESC. Stay up to date with the latest journal news.

Explore ESC Publications

Related titles

• X (formerly Twitter)
• Recommend to Your Librarian
• Journals Career Network

Affiliations

• Online ISSN 1755-3245
• Print ISSN 0008-6363
• Copyright © 2024 European Society of Cardiology
• About Oxford Academic
• Publish journals with us
• University press partners
• What we publish
• New features  
• Open access
• Institutional account management
• Rights and permissions
• Get help with access
• Accessibility
• Advertising
• Media enquiries
• Oxford University Press
• Oxford Languages
• University of Oxford

Oxford University Press is a department of the University of Oxford. It furthers the University's objective of excellence in research, scholarship, and education by publishing worldwide

• Copyright © 2024 Oxford University Press
• Cookie settings
• Cookie policy
• Privacy policy
• Legal notice

This Feature Is Available To Subscribers Only

Sign In or Create an Account

This PDF is available to Subscribers Only

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

An official website of the United States government

Official websites use .gov A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS A lock ( Lock Locked padlock icon ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

• Publications
• Account settings
• Advanced Search
• Journal List

The year in cardiovascular medicine 2021: acute cardiovascular care and ischaemic heart disease

Susanna price, christoph c kaufmann.

• Author information
• Article notes
• Copyright and License information

Corresponding author. Email: [email protected]

Received 2021 Dec 15; Accepted 2021 Dec 23; Collection date 2022 Feb 21.

This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model )

This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.

Graphical Abstract

Graphical abstract..

Mechanisms and clinical phenotypes: the potential impact of acute COVID-19 on the heart and its longer-term sequelae. Reprinted with permission from: Friedrich MG, Cooper LT Jr. What we (don’t) know about myocardial injury after COVID-19. Eur Heart J 2021; 42 :1879–1882.

Keywords: Acute cardiac care, Acute coronary syndromes, Ischaemic heart disease, Cardiogenic shock, COVID-19

In a year when COVID-19 continued to dominate healthcare, its impact on cardiovascular disease in the acute and emergency settings remained evident. The cardiovascular literature documented persistent disruption in healthcare delivery, with continued reduction in patients presenting with ST-segment elevation myocardial infarction (STEMI) and increased late presentations of STEMI, infarct size, and complications, 1 , 2 delay in revascularization, 3 reduction in admissions for acute heart failure (AHF), and an associated increased in-hospital AHF mortality. 4 The extent, nature, and aetiology of COVID-19-related cardiac injury were the focus of numerous studies, 5 , 6 PIMS-TS (paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2) became well recognized as a disease entity with potential significant cardiac involvement, and defined diagnostic criteria and treatment strategies. 7 , 8 The important but rare side effect of mRNA vaccine-related myocarditis emerged, 9 and the syndrome of thrombosis with thrombocytopaenia after ChAdOx1 NcoV-19 vaccination 10 prompted development of a novel score (FAPIC) to predict mortality. 11 Despite this immense disruption to healthcare, significant advances were nonetheless made in the fields of acute coronary syndromes (ACS), ischaemic heart disease, and acute cardiovascular care, with a number of important papers published in the European Heart Journal and elsewhere that significantly furthered our knowledge in these fields.

Pathophysiology

It is well recognized that not all patients with coronary artery atheroma develop an acute myocardial infarction (AMI), but the reasons why are less well understood. In this context, Hartiala and co-workers postulated that genetic factors for atherosclerosis might differ from those predisposing to plaque vulnerability, erosion, rupture or thrombosis. 12 Based on a meta-analysis of genome-wide association study (GWAS) data from the UK Biobank and CARDIoGRAMplusC4D consortium, they performed multiple independent replication analyses and functional approaches, to prioritize loci and evaluate candidate genes for MI. They established eight novel genetic risk loci for MI, with six showing a stronger effect size for MI vs. atheroma. Additionally, a locus on chromosome 1p21.3 harbouring the choline-like transporter 3 gene (SLC44A3) was significantly associated with MI in those with coronary atheroma, but not with lifetime risk of coronary atherosclerosis. Further, the SLC44A3 locus was unrelated to cardiovascular risk factors, prothrombotic biomarkers, and a series of proatherosclerotic metabolites. It was, however, expressed in the aorta of carriers of the AMI risk allele at chromosome 1p21.3, increased in ischaemic coronary arteries, and associated with smooth muscle cell migration in vitro , thus potentially implicating SLC44A3 in the pathophysiology of vulnerable plaques ( Figure 1 ).

Key findings from the Hartiala study determining distinct genetic risk factors for MI. Here, acting on a normal vessel, known genetic risk factors for CAD lead to plaque initiation and progression; subsequently, two distinct risk factors act, resulting in plaque rupture and thrombus formation. MI, myocardial infarction; CAD, coronary artery disease. Reprinted with permission from Hartiala et al . 12

New clues regarding plaque erosion emerged from the prospective, multicentre study OPTICO-ACS. 13 Here Leistner and colleagues analysed the microenvironment of culprit plaques in 170 ACS patients integrating in vivo high-resolution optical coherence tomography (OCT) imaging and the local immune response ( Figure 2 ). Intact fibrous cap (IFC) was characterized by lower lipid content, less calcification, and localization near a coronary bifurcation when compared with ruptured fibrous cap (RFC-ACS). The microenvironment of IFC-ACS lesions showed selective enrichment in T lymphocytes (predominantly CD8+) and higher T-cell-associated extracellular circulating microvesicle levels. Further, significantly higher numbers of CD8+ T lymphocytes were detectable in thrombi aspirated from IFC-culprit sites and higher levels of soluble cytotoxic effector mediators. Finally, co-culture demonstrated the proapoptotic effect of CD8+ T cells and their cytotoxic effector molecules on endothelial cells, and in vivo experiments showed enhanced adhesion of CD8+ T cells to endothelial cells subjected to culture in disturbed (vs. laminar) flow conditions. Whether T-cell activation is a key step in the sequence leading to plaque erosion and thrombus formation, or an epiphenomenon, remains to be determined.

A graphical abstract summarizing the main features and findings of the OPTICO-ACS study. STE, ST elevation; NSTE, non-ST elevation; ACS, acute coronary syndrome; OCT, optical coherence tomography; CL, culprit lesion; IFC, intact fibrous cap; RFC, ruptured fibrous cap; NK, natural killer cell. Reprinted with permission from Leistner et al . 13

Appreciation of inflammation in cardiovascular disease has prompted the search for additional mechanisms, including those where remote events may worsen/accelerate plaque formation. Kyaw and co-workers used an apolipoprotein-E-deficient (ApoE−/−) mouse model of MI-accelerated atherosclerosis to assess the importance of B cells in accelerated plaque formation. 14 Here, 1-week post-MI B cells were depleted using an anti-CD20 antibody, resulting in attenuation of IgG accumulation in plaques and MI-induced accelerated atherosclerosis. Further, adoptive transfer of reactive B cells into atherosclerotic ApoE−/− mice without MI increased IgG accumulation in plaque, and accelerated atherosclerosis. These findings suggest that B cells are key for lesion enhancement, and suggest that MI could potentially worsen atheroma via the development of autoimmunity against the vessel wall through autoreactive B-cell memory. If these findings transfer to humans, the implications for secondary prevention strategies are significant.

Recognition of the potential role of white blood cell subtypes has resulted in numerous studies evaluating their role in the mechanism and risk prediction in cardiovascular disease. Adamstein and co-workers performed an analysis of the neutrophil–lymphocyte ratio (NLR) from five major randomized controlled trials (RCTs). 15 Collecting baseline and on-treatment NLRs in ∼60 000 participants, they aimed to determine whether the NLR predicts incident major adverse cardiovascular events and is modified by anti-inflammatory therapy. They demonstrated that baseline NLR consistently and independently predicted cardiovascular events and death, and although lipid-lowering agents had no significant impact, NLR decreased during canakinumab therapy. This readily available biomarker could in future be used for risk stratification and potentially to guide anti-inflammatory treatment; however, the biological basis for these findings, and their potential effects on outcomes, demand further evaluation.

Cardiovascular risk and biomarkers

A pre-specified analysis of the SWEDEHEART registry revealed that STEMI patients without standard modifiable cardiovascular risk factors (SMuRFs) have significantly increased risk of early all-cause mortality (females, 17.6%; males, 9.6%) compared with patients with ≥1 SMuRF (females, 11.1%; males, 6.3%; P < 0.0001). 16 After correction for confounders, this difference persisted, but disappeared after inclusion of guideline-recommended pharmacotherapy at discharge. The authors concluded that evidence-based optimal pharmacotherapy at discharge should be given to ‘low-risk’ patients to reduce mortality.

To identify predictors of future type 1 and type 2 MI within 1-year follow-up, the High-STEACS investigators conducted a secondary analysis of a trial population of >48 000 consecutive patients presenting with suspected ACS. 17 Risk factors for recurrent MI included age, diabetes, hyperlipidaemia, known coronary artery disease, and renal dysfunction ( P < 0.05).

The range of biomarkers to enhance diagnosis in the emergency setting is increasing. Neumann and colleagues investigated the discriminative value of 29 biomarkers in the emergency room to differentiate type 1 and type 2 MI, and myocardial injury. 18 By multivariate analysis, N-terminal probrain natriuretic protein (NT-proBNP), copeptin, apolipoprotein AII, and cardiac troponin I (cTnI) remained significant discriminators between type 1 and type 2 MI. For discrimination between MI and myocardial injury, adiponectin, NT-proBNP, cTnI, copeptin, transthyretin, and pulmonary and activation-regulated chemokine were selected. In both discriminations, internal validation showed an area under the curve >0.8. In contrast, the utility of some older biomarkers is increasingly questioned. Last year (2021) may signal the end of the use of CK-MB (creatine kinase myocardial band), with reasons proposed including its lower sensitivity in detecting myocardial injury/infarction compared with cardiac troponin, lack of additional value for risk stratification in suspected MI, temporal appearance, and poor performance in re-infarction/peri-procedural myocardial injury. 19

Clinical outcomes

Even in the acute setting, long-term outcomes are important. A study compared long-term all-cause and cardiovascular mortality among 3829 adults (median age 44 years; 30% women) presenting with type 1 MI (55%), type 2 MI (32%), or myocardial injury (13%). 20 Long-term mortality (>10 years) was lowest for type 1 MI (12%), followed by type 2 MI (34.2%) and myocardial injury (45.6%) ( P < 0.001). Those with myocardial injury/type 2 MI were younger, had fewer classical cardiovascular risk factors, but increased non-cardiovascular co-morbidities. Accordingly, their all-cause mortality was significantly higher [hazard ratio (HR) 1.8; 95% confidecne interval (CI) 1.2–2.7; P ≤ 0.004]. Cardiovascular mortality was also higher in this group (HR 2.7; 95% CI 1.4–5.1; P = 0.003); however, many had suboptimal therapy at discharge.

There is little information regarding long-term outcomes in patients with late-presentation STEMI (12–48 h after symptom onset). In a nationwide prospective Korean registry, Hoon and colleagues investigated 624 late-presenting STEMI patients compared with early presenters (<12 h of symptom onset; n = 5202) for 180-day and 3-year mortality. 21 As expected, late presenters had a significantly higher all-cause mortality after 180 days (10.7 vs. 6.8%; P < 0.001) and 3 years (16.2 vs. 10.6%; P < 0.001) attributed in part to fewer percutaneous coronary intervention (PCI) procedures (acute and total) in late presenters. Future studies should determine those late presenters that might benefit from intervention.

Therapeutic strategies

Two studies addressed the role of inflammation in cardiovascular disease. In AMI, Broch et al . performed a randomized trial of tocilizumab ( n = 101) vs. placebo ( n = 98) in patients with STEMI within 6 h of symptom onset in order to evaluate its effect on myocardial salvage. 22 They reported a significantly larger myocardial salvage index in tocilizumab-treated patients compared with placebo (adjusted difference 5.6%; 95% CI 0.2–11.3; P < 0.04). To date, the clinical significance remains uncertain, and larger studies are required to investigate the effects on clinical endpoints. A number of RCTs have demonstrated a benefit of the addition of low-dose colchicine to guideline-based treatment in patients with recent MI or chronic coronary disease. Fiolet and colleagues performed a systematic review and meta-analysis of five trials comprising 11 816 patients with the aim to determine major adverse cardiac events (MACE; composite of MI, stroke, or cardiovascular death). 23 Their findings showed that colchicine reduced the risk for the primary endpoint by 25% [relative risk (RR) 0.75; 95% CI 0.61–0.92] ( Figure 3 ).

Key findings from a meta-analysis of five studies determining the effects of colchicine on MACE including risk reduction and potential mechanisms. MACE, major adverse cardiovascular events. Reprinted with permission from Fiolet et al . 23

Optimal transfusion thresholds in AMI remain uncertain. The French REALTY (Restrictive and Liberal Transfusion Strategies in Patients With Acute Myocardial Infarction) investigators aimed to determine whether a restrictive transfusion strategy (haemoglobin trigger ≥8 g/dL) was non-inferior to a liberal strategy (haemoglobin trigger ≥10 g/dL) in AMI. 24 The restrictive strategy (11%; 95% CI −8.4 to 2.4%) fulfilled the non-inferiority criterion vs. the liberal strategy (14%; 95% CI 10.0–17.9%) for the composite outcome of all-cause death, stroke, recurrent MI, or emergency revascularization at 30 days.

Debate concerning antithrombotic therapy post-PCI continues. Two post-hoc analyses of the TWILIGHT trial, comparing short (3-month) dual antiplatelet therapy (DAPT) with aspirin and ticagrelor followed by ticagrelor monotherapy up to 12 months vs. 12-month DAPT in high- and very high-risk patients undergoing PCI and stent implantation, were recently published. The TWILIGHT-CKD trial studied the impact of chronic kidney disease, demonstrating that ticagrelor monotherapy when started early significantly reduced the risk of bleeding without significantly increasing thrombo-ischaemic endpoints (combination of death, MI, stroke; all-cause death; MI; stent thrombosis). 25 Comparable results were demonstrated in the TWILIGT-HBR study where patients with high bleeding risk (HBR) with 3 months DAPT (aspirin plus ticagrelor followed by ticagrelor monotherapy) vs. 12 months DAPT exhibited significantly reduced bleeding without an increase in ischaemic events. 26 In a meta-analysis of patients with HBR after revascularization receiving short (1 month) vs. longer (3–6 month) DAPT (aspirin + different P2Y 12 inhibtors, followed by P2Y 12 inhibitor monotherapy), Valgimigli et al . reported that early P2Y 12 inhibitor monotherapy showed comparable risk of death, MI, or stroke but significantly lower bleeding risk compared with prolonged DAPT. 27 It seems therefore that shortening of DAPT in patients undergoing PCI is associated with significantly less bleeding and no increase in risk of thrombo-ischaemic events.

Resuscitation science

Out-of-hospital cardiac arrest (OHCA) remains a major public health challenge with a global incidence of 55/100 000 person-years and poor survival. There is ongoing discussion regarding management priorities, in particular in post-resuscitation care.

Aiming to determine whether routine immediate coronary angiography potentially followed by revascularization is superior to a deferred/selective approach, the TOMAHAWK investigators examined all-cause 30-day mortality in 558 pateints with haemodynamically stable resuscitated OHCA without STEMI. 28 Outcomes were not significantly different between patient groups, suggesting that—if stable—it is appropriate to prioritize immediate post-resuscitation care over angiography.

The ARREST study (Advanced reperfusion strategies for patients with out-of-hospital cardiac arrest and refractory ventricular fibrillation) aimed to determine whether implementation of early extracorporeal membrane oxidation (ECMO)-facilitated resuscitation vs. standard resuscitation improved survival. 29 This phase II single-centre open-label adaptive safety and efficacy RCT included adults with OHCA and refractory ventricular fibrillation with a primary outcome of survival to hosptial discharge. The trial was terminated at the first pre-planned interim analysis after enrolling only 30 patients because the posterior probability of ECMO superiority exceeded the pre-specified monitoring boundary (survival in 1 of 15 patients with standard resuscitation vs. 6 of 14 with early ECMO; risk difference 36.2%, 3.7–59.2; posterior probability of ECMO superiority 0.9861). The results of further randomized trials are awaited.

Two studies added to our understanding of targeted temperature management (TTM) post-arrest. First, in an open-label trial, 1900 adults with coma post-OHCA were randomized to TTM (33°C) or normothermia (≥37.8°C). 30 The primary outcome of 6-month all-cause mortality was no different between the groups. In the CAPITA-CHILL study (single-centre, double-blind randomized clinical superiority trial), 389 patients with OHCA were randomly assigned to 31°C (193 patients) vs. 24°C (196 patients) for 24 h. 31 Primary outcome was 180-day all-cause mortality/poor neurological outcome with no difference between the groups. These findings support recommendations in current resuscitation guidelines.

Systemic inflammation is a major component of the post-resuscitation syndrome. In a double-blinded placebo-controlled trial aiming to determine the efficacy of interleukin-6 (IL-6) inhibition to reduce systemic inflammation post-OHCA, 80 patients were randomized to an infusion of tocilizumab vs. placebo in addition to standard care. 32 The primary endpoint was C-reactive protein reduction from baseline, and secondary endpoints included markers of inflammation, and myocardial and brain injury. Here tocilizumab resulted in a significant reduction in inflammatory markers and myocardial injury. Whether this will translate into improved outcomes remains to be evaluated.

Cardiogenic shock

The landscape for cardiogenic shock (CS) is shifting. In a nationwide registry, changes in epidemiology, interventions, and outcomes were studied in 14 363 patients, comparing 2005 and 2017. 33 ACS as the underlying cause decreased (37.1% 2005 vs. 21.4% 2017), as did heart failure (16.3% vs. 12.0%) and arrhythmia (13.0% vs. 10.9%); however, CS complicating cardiac arrest increased significantly (11.3% vs. 2.5%). In parallel, the use of mechanical circulatory support (MCS) increased significantly, and although overall 30-day and 1-year mortality were relatively stable, there were significant decreases in those with ACS and arrhythmias. Recognizing evidence from the last 5 years, key changes regarding CS in the latest ESC guidelines included modification of the definition to increase the focus on hypoperfusion rather than hypotension, removing adrenaline as a recommended inotrope, and upgrading recommendations for acute MCS. 34

The heterogeneity of the CS population means that accurate risk stratification for individual patients and populations within clinical trials remains challenging. 35 Using data from the CULPRIT-SHOCK trial, a biomarker-based risk score for 30-day mortality was developed from 458 patients with CS complicating AMI. Of 58 candidate variables, the four strongest predictors for mortality were cystatin C, lactate, IL-6, and NT-proBNP (CLIP, Figure 4 ). 36 The score outperformed the SAPS II and IABP-SHOCK II risk scores (0.83 vs. 0.62 and 0.83 vs. 0.76, respectively) and may contribute to early decision-making in CS after AMI; however, as with all biomarker-related scores in the acute/emergency setting, point-of-care testing and turn around times remain problematic.

Development of the CLIP score in cardiogenic shock. Fifty-eight parameters were studied in patients included in the IABP SHOCK II study, and with internal and external validation a simple four-point biomarker score was developed for mortality risk stratification. IABP, intra-aortic balloon pump; SAPS, simplified Apache physiological score. Reprinted with permission from Ceglarek et al . 36

Data guiding choice of inotropic agent in CS are limited. The expanding evidence base suggesting potential harm from adrenaline has increased focus on other drugs. In the DOREMI (Dobutamine Compared with Milrinone) trial, 192 paients with CS were randomly assigned to receive milrinone or dobutamine in a double-blind fashion. 37 Here, there was no difference in the primary composite outcome (in-hospital death from any cause, resuscitated cardiac arrest, receipt of cardiac transplant or MCS, non-fatal MI, transient ischaemic attack or stroke, or inititation of renal replacement therapy) between the groups, and in-hospital mortality remained disappointingly high. Whether these findings would be replicated across all phenotypes, aetiologies, and severity of CS remains to be determined.

Conclusions

Significant advances in understanding the underlying pathological mechanisms, the role of inflammation and the immune system, and in risk stratification of our most acute and critically ill cardiac patients continue to be made. The increasing collaboration between basic and clincial science, cardiology, critical care, and acute medicine continues to drive our knowledge base further, providing the evidence that will surely underpin best practice in these most challenging areas of cardiology in the future.

Conflict of interest: none declared.

• 1. Pessoa-Amorim G, Camm CF, Gajendragadkar P, De Maria GL, Arsac C, Laroche C, et al. . Admission of patients with STEMI since the outbreak of the COVID-19 pandemic: a survey by the European Society of Cardiology. Eur Heart J Qual Care Clin Outcomes 2020;6:210–216. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ]
• 2. Lechner I, Reindl M, Tiller C, Holzknecht M, Troger F, Fink P, et al. . Impact of COVID-19 pandemic restrictions on ST-elevation myocardial infarction: a cardiac magnetic resonance imaging study. Eur Heart J 2021;42:ehab621. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ]
• 3. Tokarek T, Dziewierz A, Malinowski K, Rakowski T, Bartus S, Dudek D, et al. . Treatment delay and clinical outcomes in patients with ST-elevation myocardial infarction during the COVID-19 pandemic. Eur Heart J 2021;42(Suppl 1):ehab724.1470. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ]
• 4. Kubica-Malgorzata J, Wioleta O, Stolarek M, Kasprzak M, Grzelakowska K, Kryś J, et al. . Impact of COVID-19 pandemic on acute heart failure admissions and mortality: a multicentre study (COV-HF-SIRIO 6 study). ESC Heart Fail 2021;doi: 10.1002/ehf2.13680. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ]
• 5. Satterfield BA, Bhatt DL, Gersh BJ.. Cardiac involvement in the long-term implications of COVID-19. Nat Rev Cardiol 2021:doi: 10.1038/s41569-021-00631-3. [ DOI ] [ PMC free article ] [ PubMed ]
• 6. Kotecha T, Knight DS, Razvi Y, Kumar K, Vimalesvaran K, Thornton G, et al. . Patterns of myocardial injury in recovered troponin-positive COVID-19 patients assessed by cardiovascular magnetic resonance. Eur Heart J 2021;42:1866–1878. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ]
• 7. Schlapbach LJ, Andre MC, Grazioli S, Schöbi N, Ritz N, Aebi C, et al. . Best practice recommendations for the diagnosis and management of children with pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS; multisystem inflammatory syndrome in children, MIS-C) in Switzerland. Front Pediatr 2021;9:667507. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ]
• 8. Carter MJ, Shankar-Hari M, Tibby SM. Paediatric inflammatory multisystem syndrome temporally-associated with SARS-CoV-2 infection: an overview. Intensive Care Med 2021;47:90–93. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ]
• 9. Witberg G, Barda N, Hoss S, Richter I, Wiessman M, Aviv Y, et al. . Myocarditis after COVID-19 vaccination in a large health care organization. N Engl J Med 2021;385:2132–2139. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ]
• 10. Foltran D, Delmas C, Flumian C, De Paoli P, Salvo F, Gautier S, et al. . Myocarditis and pericarditis in adolescents after first and second doses of mRNA COVID-19 vaccines. Eur Heart J Qual Care Clin Outcomes 2021;qcab090. 10.1093/ehjqcco/qcab090. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ]
• 11. Hwang J, Park SH, Lee SW, Lee SB, Lee MH, Jeong GH, et al. . Predictors of mortality in thrombotic thrombocytopenia after adenoviral COVID-19 vaccination: the FAPIC score. Eur Heart J 2021;42:4053–4063. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ]
• 12. Hartiala JA, Han Y, Jia Q, Hilser JR, Huang P, Gukasyan J, et al. . Genome-wide analysis identifies novel susceptibility loci for myocardial infarction. Eur Heart J 2021;42:919–933. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ]
• 13. Leistner DM, Krankel N, Meteva D, Abdelwahed YS, Seppelt C, Stähli BE, et al. . Differential immunological signature at the culprit site distinguishes acute coronary syndrome with intact from acute coronary syndrome with ruptured fibrous cap: results from the prospective translational OPTICO-ACS study. Eur Heart J 2020;41:3549–3560. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ]
• 14. Kyaw T, Loveland P, Kanellakis P, Cao A, Kallies A, Huang AL. et al. Alarmin-activated B cells accelerate murine atherosclerosis after myocardial infarction via plasma cell-immunoglobulin-dependent mechanisms. Eur Heart J 2021;42:938–947. [ DOI ] [ PubMed ] [ Google Scholar ]
• 15. Adamstein NH, MacFadyen JG, Rose LM, Glynn RJ, Dey AK, Libby P, et al. . The neutrophil–lymphocyte ratio and incident atherosclerotic events: analyses from five contemporary randomized trials. Eur Heart J 2021;42:896–903. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ]
• 16. Figtee GA, Vernon ST, Hadziosmanovic N, Sundström J, Alfredsson J, Arnott C, et al. . Mortality in STEMI patients without standard modifiable risk factors: a sex-disaggregated analysis of SWEDEHEART registry data. Lancet 2021;397:1085–1094. [ DOI ] [ PubMed ] [ Google Scholar ]
• 17. Wereski R, Kimenai DM, Bulgara A, Taggart C, Lowe DJ, Mills NL, et al. . Risk factors for type 1 and type 2 myocardial infarction. Eur Heart J 2022;43:127–135. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ]
• 18. Neumann JT, Weimann J, Sörensen NA, Hartikainen TS, Haller PM, Lehmacher J, et al. . A biomarker model to distinguish types of myocardial infarction and injury. J Am Coll Cardiol 2021;78:781–790. [ DOI ] [ PubMed ] [ Google Scholar ]
• 19. Jaffe AS, Lindahl B, Giannitsis E, Mueller C, Cullen L, Hammarsten O, et al. . ESC study group on cardiac biomarkers of the Association for Acute CardioVascular Care: a fond farewell at the retirement of CKMB. Eur Heart J 2021;42:2260–2264. [ DOI ] [ PubMed ] [ Google Scholar ]
• 20. Singh A, Gupta A, DeFilippis EM, Qamar A, Biery DW, Almarzooq Z, et al. . Cardiovascular mortality after type 1 and type 2 myocardial infarction in young adults. J Am Coll Cardiol 2020;75:1003–1013. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ]
• 21. Cho KH, Han X, Ahn JH, Hyun DY, Kim MC, Sim DS, et al. . Long-term outcomes of patients with late presentation of ST-segment elevation myocardial infarction. J Am Coll Cardiol 2021;77:1859–1870. [ DOI ] [ PubMed ] [ Google Scholar ]
• 22. Broch K, Anstensrud AK, Woxholt S, Sharma K, Tollefsen IM, Bendz B, et al. . Randomized trial of interleukin-6 receptor inhibition in patients with acute ST-segment elevation myocardial infarction. J Am Coll Cardiol 2021;77:1845–1855. [ DOI ] [ PubMed ] [ Google Scholar ]
• 23. Fiolet ATL, Opstal TSJ, Mosterd A, Eikelboom JWJolly SS, Keech AC, et al. . Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials. Eur Heart J 2021;42:2765–2775. [ DOI ] [ PubMed ] [ Google Scholar ]
• 24. Ducrocq G, Gonzalez-Juanatey JR, Puymirat E, Lemesle G, Cachanado M, Durand-Zaleski I, et al. . Effect of a restrictive vs liberal blood transfusion strategy on major cardiovascular events among patients with acute myocardial infarction and anemia. JAMA 2021;325:552–560. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ]
• 25. Stefanini GG, Briguori C, Cao D, Baber U, Sartori S, Zhang Z, et al. . Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD. Eur Heart J 2021;42:4683.–. [ DOI ] [ PubMed ] [ Google Scholar ]
• 26. Escaned J, Cao D, Baber U, Nicolas J, Satori S, Zhank Z, et al. . Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR. Eur Heart J 2021;42:4624–4634. [ DOI ] [ PubMed ] [ Google Scholar ]
• 27. Valgimigli M, Gragnano F, Branca M, Franzone A, Baber U, Jang Y, et al. . P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials. BMJ 2021;373:n1332. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ]
• 28. Desch S, Freund A, Akin I, Behnes M, Preusch MR, Zelniker TA, et al. . Angiography after out-of-hospital cardiac arrest without ST-segment elevation. N Engl J Med 2021;doi: 10.1056/NEJMoa2101909. [ DOI ] [ PubMed ] [ Google Scholar ]
• 29. Yannopoulos D, Bartos J, Raveendran G, Walser E, Connett J, Murray TA, et al. . Advanced reperfusion strategies for patients with out-of-hospital cardiac arrest and refractory ventricular fibrillation (ARREST): a phase 2, single centre, open-label, randomised controlled trial. Lancet 2020;396:1807–1816. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ]
• 30. Dankiewicz J, Cronberg T, Lilja G, Jakobsen JC, Levin H, Ullén S, et al. . Hypothermia versus normothermia after out-of-hospital cardiac arrest. N Engl J Med 2021;384:2283–2294. [ DOI ] [ PubMed ] [ Google Scholar ]
• 31. Le May M, Osborne C, Russo J, So D, Chong AY, Dick A, et al. . Effect of moderate vs mild therapeutic hypothermia on mortality and neurologic outcomes in comatose survivors of out-of-hospital cardiac arrest: the CAPITAL CHILL randomized clinical trial. JAMA 2021;326:1494–1503. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ]
• 32. Meyer MAS, Wiberg S, Grand J, Meyer ASP, Obling LER, Frydland M, et al. . Treatment effects of interleukin-6 receptor antibodies for modulating the systemic inflammatory response after out-of-hospital cardiac arrest (the IMICA trial): a double-blinded, placebo-controlled, single-center, randomized, clinical trial. Circulation 2021;143:1841–1851. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ]
• 33. Petersen LT, Riddersholm S, Andersen DC, Polcwiartek C, Lee CJ-Y, Lauridsen MD, et al. . Temporal trends in patient characteristics, presumed causes, and outcomes following cardiogenic shock between 2005 and 2017: a Danish registry-based cohort study. Eur Heart J Acute Cardiovasc Care 2021;10:1074–1083. [ DOI ] [ PubMed ] [ Google Scholar ]
• 34. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. . 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599–3726. [ DOI ] [ PubMed ] [ Google Scholar ]
• 35. Arrigo M, Price S, Baran DA, Pöss J, Aissaoui N, Bayes-Genis A, et al. . Optimising clinical trials in acute myocardial infarction complicated by cardiogenic shock: a statement from the 2020 Critical Care Clinical Trialists Workshop. Lancet Respir Med 2021;9:1192–1202. [ DOI ] [ PubMed ] [ Google Scholar ]
• 36. Ceglarek U, Schellong P, Rosolowski M, Scholz M, Willenberg A, Kratzsch J, et al. . The novel cystatin C, lactate, interleukin-6, and N-terminal pro-B-type natriuretic peptide (CLIP)-based mortality risk score in cardiogenic shock after acute myocardial infarction. Eur Heart J 2021;42:2344–2352. [ DOI ] [ PubMed ] [ Google Scholar ]
• 37. Mathew R, Di Santo P, Jung RG, Marbach JA, Hutson J, Simard T, et al. . Milrinone as compared with dobutamine in the treatment of cardiogenic shock. N Engl J Med 2021;385:516–525. [ DOI ] [ PubMed ] [ Google Scholar ]
• View on publisher site
• PDF (1016.4 KB)
• Collections

Similar articles

Cited by other articles, links to ncbi databases.

• Download .nbib .nbib
• Format: AMA APA MLA NLM

Add to Collections